| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2023-033 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 第五届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、西藏奇正藏药股份有限公司（以下简称"公司"）第五届董事会第二十四 次会议于 2023 年 8 月 14 日以通讯形式召开； 2、会议通知于 2023 年 8 月 9 日以电子邮件、电话、信息等方式发出； 3、会议应参加表决董事 7 人，实际参加表决董事 6 人，其中独立董事 3 名， 公司监事及高级管理人员列席了会议； 4、会议由公司董事长雷菊芳女士召集并主持； 5、本次会议的出席人数、召集召开程序、议事内容符合《公司法》和《公 司章程》的相关规定。 二、董事会会议审议情况 1、审议通过了《关于 2019 年限制性股票激励计划首次授予权益第四个解除 限售期解除限售条件成就的议案》。 公司2019年限制性股票激励计划首次授予权益第四个解除限售 ...

证券代码：002287 证券简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司 投资者关系活动记录表 编号：2023-002 | --- | |---------------------------| | √特定对象调研 □分析师会议 | | □媒体采访 □业绩说明会 | | □新闻发布会 □路演活动 | | □现场参观 | | □其他 | 投资者关系活动类 别 东方证券 刘恩阳；民生加银 李由；民生证券 王班、 宋丽莹；华创证券 胡健东；远策投资 赵潘；招商基金 张馨洋；华泰证券 张云逸；博时基金 李帅；中信建投 高庆勇；人保资产 田露瑶；招银理财 葛斌；银华基金 吴颖；财通证券 邢卓；光大保德信 张翔宇。 公司董事、总裁 刘凯列；副总裁 李军；副总裁、董事 会秘书 冯平；财务总监 姚晓梅；副总裁 夏海建 活动参与人员 时间 2023 年 06 月 15 日（星期四）9:30-11:30 地点 公司北京会议室及腾讯会议 形式 线下+线上 | --- | --- | |--------------------------------------------------|--- ...

证券代码：002287 证券简称：奇正藏药 | 实现业绩增长。谢谢！ | | --- | | 10、问：请问终端医院的覆盖数量和节奏，今年目标覆 | | 盖到多少家？ | | 答：您好！公司已覆盖上万家终端医院，每年公司会按 | | 照覆盖计划进行市场推进，渠道方面，加强基层和区域 | | 分级渗透，城市覆盖从战略初期的 100 个，增加到战略 | | 末期的 180+。终端覆盖数量持续增长。谢谢！ | | 11、问：想问一下领导对中成药口服药的市场空间怎么 | | 预计？公司如意珍宝片未来的推广计划和销售策略是怎 | | 样的？ | | 答：您好！公司重点关注口服藏成药红花如意丸、如意 | | 珍宝片的成长，产品市场空间均在 1 亿元以上。如意珍 | | 宝片推广主要面向两个方向，其一针对骨骼肌肉神经性 | | 疼痛，其二针对脑卒中后遗症。公司将持续展开如意珍 | | 宝片更多循证医学证据研究，为上述疾病的临床治疗提 | | 供更多选择方案。谢谢！ | | 12、问：请问公司对百洋医药的投资有什么打算。 | | 答：您好！2023 年 3 月 21 日，公司收到群英投资函 | | 告，向全体合伙人分配群英投 ...

为便于广大投资者进一步了解西藏奇正藏药股份有限公司（以下简称"公 司"）经营情况，公司定于2023年5月12日（星期五）15:00—17:00在"奇正藏 药投资者关系"小程序举行2022年度报告业绩说明会，就公司发展战略、生产经 营情况与投资者进行充分交流，广泛听取投资者的意见和建议。 届时出席本次业绩说明会的人员有：公司董事、总裁刘凯列先生，副总裁李 军先生，副总裁、董事会秘书冯平女士，财务总监姚晓梅女士，副总裁赵敏女士， 独立董事李春瑜先生。 本次业绩说明会采用网络远程的方式举行，为广泛听取投资者的意见和建 议，提前向投资者征集问题，提问通道自发出公告之日起开放，投资者可通过以 下方式参与互动交流。 参与方式一：微信扫一扫"奇正藏药投资者关系平台"微信公众号二维码， 在"投关"中进入投资者关系活动，即可参与交流； | 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2023-021 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于举行 2022 年度报告业绩说明会的公告 本公司及董事会全体成员保证信息披露内 ...

Financial Performance - The company's operating revenue for 2022 was CNY 2,044,789,340.21, representing a 15.49% increase compared to CNY 1,770,485,989.72 in 2021[12]. - The net profit attributable to shareholders for 2022 was CNY 440,018,192.00, which is a 27.57% increase from CNY 344,932,156.80 in 2021[12]. - The basic earnings per share for 2022 decreased to CNY 0.8919, down 34.14% from CNY 1.3542 in 2021[12]. - The net cash flow from operating activities for 2022 was CNY 285,686,729.21, a decrease of 72.40% compared to CNY 1,034,917,529.72 in 2021[12]. - The company reported a net loss from the disposal of non-current assets amounting to -159,828.88 yuan in 2022, compared to a profit of 72,823,720.13 yuan in 2021, indicating a significant decline in asset disposal performance[38]. - The fair value changes and disposal gains from trading financial assets amounted to 41,611,008.20 yuan in 2022, up from 28,662,428.66 yuan in 2021, reflecting improved trading performance[38]. - The company experienced a substantial decrease in other non-operating income and expenses, reporting -52,785,637.84 yuan in 2022, down from 294,826,622.00 yuan in 2021, primarily due to equity investment losses[38]. - The tax impact of non-recurring gains and losses was 4,193,302.39 yuan in 2022, compared to 38,796,178.22 yuan in 2021, indicating a reduced tax burden from non-recurring items[38]. - Investment income decreased by ¥33,652,366.41, accounting for -6.48% of total profit due to losses from long-term equity investments and financial products[93]. - Fair value changes resulted in a loss of ¥3,429,422.25, representing -0.66% of total profit, attributed to the measurement of trading financial assets at fair value[93]. - Other income increased to ¥72,995,779.05, making up 14.06% of total profit, primarily from government subsidies and deferred income[93]. Assets and Liabilities - The total assets at the end of 2022 were CNY 5,886,644,252.44, a 5.73% increase from CNY 5,567,753,848.57 at the end of 2021[12]. - Cash and cash equivalents at the end of 2022 were ¥437,571,379.17, constituting 7.43% of total assets, down from 11.97% at the beginning of the year[93]. - Accounts receivable rose to ¥102,418,409.81, representing 1.74% of total assets, an increase of 1.19% compared to the beginning of the year[93]. - Inventory increased to ¥127,774,134.44, accounting for 2.17% of total assets, a slight rise from 2.13% at the beginning of the year[93]. - The total amount of financial assets at the end of the period was ¥2,888,316,080.27, with a fair value change loss of -¥3,123,054.96[94]. Research and Development - The company holds 155 patents, including 126 invention patents, and was ranked 31st in the "2022 China Traditional Chinese Medicine R&D Strength Ranking TOP50"[22]. - The company is actively involved in the research and development of traditional Tibetan medicine, aiming to modernize and industrialize its offerings[84]. - The company is focusing on modernizing traditional Tibetan medicine, enhancing product quality, and expanding clinical applications to improve patient safety and efficacy[44]. - The company is building a digital platform for R&D management and an integrated R&D platform for Tibetan medicine products[142]. - The company launched the "Demonstration Development Research of Tibetan Medicine for Major Diseases" and completed the research work, providing Tibetan medicine solutions for acute stroke and diabetic peripheral neuropathy[139]. - The company published 15 SCI articles and had products like pain relief patches and Qingpeng ointment included in 18 guidelines/expert consensus documents[139]. Market Strategy and Product Development - The company plans to expand its product offerings, which currently include 141 approved products, focusing on external and oral Tibetan medicine[24]. - The company has developed a marketing strategy to promote traditional Tibetan medicine in mainstream markets and retail pharmacies, increasing brand recognition among consumers[47]. - The company offers a range of products, including pain relief patches and oral medications, with several items covered by national medical insurance, enhancing market access[45]. - The company aims to optimize its product indications and marketing strategies through evidence-based medicine research, targeting specific therapeutic areas[47]. - The company focuses on the advantages of Tibetan medicine, continuously enriching its product line, with pain relief products like pain relief patches and Qingpeng ointment seeing sustained sales growth[138]. - The pain relief patch has maintained its position as one of the top three external traditional Chinese medicine products in orthopedics, with a compound annual growth rate (CAGR) exceeding 80% over the past three years[138]. - The oral product Ruyi Zhenbao Pian has entered the national negotiation directory, achieving a CAGR of nearly 300%[138]. - The company has expanded its product portfolio in pediatrics, digestion, and cardiovascular fields through acquisitions, including the control of Tibet Tibetan Medicine Group[138]. - The company’s gynecological product Honghua Ruyi Wan has entered the national negotiation directory, providing a Tibetan medicine solution for chronic inflammatory diseases[138]. - Multiple products, including flu pills, have been included in the Tibetan medicine prevention and treatment plans for infectious respiratory diseases in several provinces, receiving clinical recognition[138]. Challenges and Risks - The company is facing challenges due to healthcare cost control and ongoing reforms in the pharmaceutical supply side, which may impact future performance[20]. - The normalization of medical insurance negotiations and the DRG/DIP system may lead to reduced drug prices and profit margins for pharmaceutical companies, posing potential profitability risks[144]. - The company emphasizes the importance of risk awareness regarding future development statements, clarifying that these do not constitute binding commitments to investors[50]. Corporate Structure and Governance - The company has 21 wholly-owned and holding subsidiaries, including GMP pharmaceutical factories and GSP marketing companies, indicating a robust operational structure[83]. - The company is recognized as a national-level high-tech enterprise and has been included in the national torch program, highlighting its innovation capabilities[83]. - The company has established independent financial management systems and ensures no interference from controlling shareholders in financial decisions[155]. - The company has set up various functional departments to ensure independent operations without interference from controlling shareholders[154]. - The company’s board includes independent directors and a diverse management team with extensive experience in the pharmaceutical industry[175][176]. - The company’s management team includes professionals with leadership roles in various pharmaceutical associations, enhancing its industry influence[175]. Employee Development and Training - In 2022, the company optimized its compensation system to maintain internal and external competitiveness, implementing a marketing bonus policy to encourage high growth and output[198]. - The company provided training programs tailored to employees' development needs, including the "Eagle 60-Day Training Camp" for new hires, with 290 participants across 5 sessions[198]. - A total of 20 individuals achieved certification as junior internal trainers through the "Internal Trainer Selection and Training" project during the reporting period[199]. Future Plans - The strategic plan for 2023-2025 is "dual-wheel drive, dual-wing leadership, dual-base guarantee"[140]. - The company is actively developing a digital shared platform to enhance overall operational efficiency and is focusing on organizational restructuring to improve leadership and attract high-quality talent[110]. - The company plans to expand its marketing network and improve its production line, with significant investments in ongoing projects[103].

证券代码：002287 证券简称：奇正藏药 公告编号：2023-019 债券代码：128133 债券简称：奇正转债 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 3.第一季度报告是否经审计 （一） 主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|-----------------|----------------|--------------------------------| | | 本报告期 | 上年同期 | 减（%） | | 营业收入（元） | 295,933,466.90 | 407,575,576.83 | -27.39% | | 归属于上市公司股东的净利润 （元） | 92,763,157.33 | 87,085,414.41 | 6.52% | | 归属于上市公司股东的扣除非经 常性损益的净利润（元） | 31,579,085.46 | 117,686,008.81 | -73.17% | | 经营活动产生 ...

证券代码：002287 证券简称：奇正藏药 编号：2016-001 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 光大永明资产管理股份有限公司 研究员 孙伟娜 岳苗 | | 人员姓名 | | 东兴证券股份有限公司 研究员 张金洋 胡偌碧 | | | | 方正证券股份有限公司 分析师 孔令岩 | | 时间 | 2016 年 7 月 6 | 日 11:00-12:00 | | 地点 | 北京市朝阳区北四环东路 | 131 号中国藏学研究中心 5 层公司 | | | 会议室 | | ...

证券代码：002287 证券简称：奇正藏药 编号：2020-002 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 北京天蝎座资产管理有限公司副总裁贾纯冶 | | 时间 | 2020 年 7 月 14 | 日 9:00-10:00 | | 地点 | 腾讯会议 | | | 上市公司接待人 | 董事会秘书：冯平 | | | 员姓名 | 证券事务代表：李阳 | | | 投资者关系活动 | 1 | 、介绍公司基本情况 | | 主要内容介绍 | | 答：感谢您对藏药及公 ...

证券代码：002287 证券简称：奇正藏药 编号：2020-001 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 东腾创新投资股份有限公司王安亚总经理 | | 时间 | 2020 年 6 月 9 | 日 16:00-17:00 | | 地点 | 腾讯会议 | | | 上市公司接待人 | 董事会秘书：冯平 | | | 员姓名 | 证券事务代表：李阳 | | | 投资者关系活动 | 1 | 、请介绍一下公司现在的业务模式。 | | 主要内容介绍 | | 答：感谢您对藏 ...

证券代码：002287 证券简称：奇正藏药 编号：2019-001 | --- | --- | --- | |-----------------------|-----------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 上海德韬投资有限公司 张成刚 | | | 人员姓名 | | 中银国际证券股份有限公司保定东风中路证券营业部 吕洋 | | 时间 | 2019 年 10 月 29 | 日 14:30-16:00 | | 地点 | 北京市朝阳区望京北路 | 9 号叶青大厦 D 座 7 层 | | 上市公司接待人 员姓名 | 证券事务代表：李阳 | | | 投资者关系活动 | | 证券事务代表李阳先生介绍藏医药、公司基本情况， ...